Keytruda 100mg Injection

About Keytruda 100mg Injection

Keytruda 100mg Injection contains Pembrolizumab, an advanced immunotherapy medicine that belongs to a class of drugs known as immune checkpoint inhibitors. It is used to treat a wide range of cancers, including melanoma (skin cancer), lung cancer, bladder cancer, stomach cancer, liver cancer, gallbladder cancer, cervical cancer, kidney cancer, colorectal cancer, esophageal cancer, breast cancer, uterine cancer, head and neck cancers, and classical Hodgkin lymphoma. Pembrolizumab works by enhancing the body's immune system to recognize and attack cancer cells more effectively, helping to slow tumor growth and improve treatment outcomes. In some patients with advanced or metastatic cancers, Keytruda 100mg Injection has demonstrated long-lasting responses and improved overall survival; however, individual results may vary, and not all patients respond to treatment in the same way. This medication is generally not recommended for children and adolescents under 18 years of age, except for children aged 3 years and older with classical Hodgkin lymphoma where its use may be appropriate. Women of childbearing potential should use effective contraception during treatment and for at least four months after the final dose, as Pembrolizumab may cause harm to an unborn baby. Before starting therapy, patients should discuss their medical history, cancer type, previous treatments, and potential risks and benefits with their healthcare provider. Regular monitoring is essential during treatment to detect and manage possible immune-related side effects that may affect organs such as the lungs, liver, intestines, kidneys, skin, and hormone-producing glands. Keytruda 100mg Injection has become an important treatment option in modern oncology, offering new hope for patients with various advanced cancers.